U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 3Cl.Cr.6H2O
Molecular Weight 266.447
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHROMIC CHLORIDE

SMILES

O.O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cr+3]

InChI

InChIKey=LJAOOBNHPFKCDR-UHFFFAOYSA-K
InChI=1S/3ClH.Cr.6H2O/h3*1H;;6*1H2/q;;;+3;;;;;;/p-3

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Cr
Molecular Weight 51.9961
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chromium sulfate(III) hexahydrate or chromium sulphate, a trivalent compound of chromium that was investigated as a toxic compound. Experiments on rodent have shown chromium sulfate produced severe and widespread effects in the nasal cavity, larynx, lungs, and mediastinal lymph node. Effects were characterized by the accumulation of foreign material, infiltration of alveolar macrophages, septal cell hyperplasia, and granulomatous and chronic inflammation. Besides, chromium sulphate exerted a disadvantageous effect on the skeleton, as it decreases bone density and resistance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CHROMIUM

Approved Use

Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Launch Date

2005
PubMed

PubMed

TitleDatePubMed
Activation of MAPKs in human bronchial epithelial cells exposed to metals.
1998 Sep
Thirteen-week subchronic rat inhalation toxicity study with a recovery phase of trivalent chromium compounds, chromic oxide, and basic chromium sulfate.
1999 Dec
Status of antioxidant defense system in chromium-induced Swiss mice tissues.
2004 Jul
Immunosuppressive effect of subchronic exposure to a mixture of eight heavy metals, found as groundwater contaminants in different areas of India, through drinking water in male rats.
2007 Oct
The peripheral quantitative computed tomographic and densitometric analysis of skeletal tissue in male Wistar rats after chromium sulfate treatment.
2017 Sep 21
Patents

Patents

Substance Class Chemical
Created
by admin
on Fri Dec 15 15:59:12 GMT 2023
Edited
by admin
on Fri Dec 15 15:59:12 GMT 2023
Record UNII
KB1PCR9DMW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHROMIC CHLORIDE
ORANGE BOOK   USP   VANDF  
Common Name English
CHROMIC CHLORIDE [VANDF]
Common Name English
Chromium(3+) chloride hexahydrate
Systematic Name English
CHROMIC CHLORIDE HEXAHYDRATE [VANDF]
Common Name English
Chromic chloride hexahydrate [WHO-DD]
Common Name English
CHROMIC CHLORIDE [USP MONOGRAPH]
Common Name English
CHROMIUM (AS CHROMIC CHLORIDE) [VANDF]
Common Name English
CHROMIC CHLORIDE [ORANGE BOOK]
Common Name English
Code System Code Type Description
CHEBI
53351
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
DRUG BANK
DB09129
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
CAS
10060-12-5
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
RXCUI
21009
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY RxNorm
SMS_ID
100000164482
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
CONCEPT Dietary Supplement
EVMPD
SUB22079
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
ALTERNATIVE
EPA CompTox
DTXSID1041001
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
DAILYMED
KB1PCR9DMW
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
EVMPD
SUB179040
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
DRUG CENTRAL
5118
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
NCI_THESAURUS
C61675
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
PUBCHEM
104957
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200528
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
FDA UNII
KB1PCR9DMW
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
EVMPD
SUB13360MIG
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
MESH
C022990
Created by admin on Fri Dec 15 15:59:12 GMT 2023 , Edited by admin on Fri Dec 15 15:59:12 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY